OAM
ENTA icon

Oxford Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Oxford Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-23,762
Closed -$137K – 541
2024
Q4 		$137K Buy
+23,762
New +$228K 0.06% 375
2020
Q1 		– Sell
-13,203
Closed -$816K – 555
2019
Q4 		$816K Sell
13,203
-6,329
-32% -$392K 0.02% 980
2019
Q3 		$1.17M Buy
19,532
+5,257
+37% +$391K 0.03% 850
2019
Q2 		$1.21M Buy
+14,275
New +$1.28M 0.03% 884
2018
Q4 		– Sell
-3,762
Closed -$333K – 1864
2018
Q3 		$333K Sell
3,762
-35,264
-90% -$3.53M 0.01% 1469
2018
Q2 		$4.51M Buy
39,026
+6,655
+21% +$664K 0.09% 248
2018
Q1 		$2.62M Buy
32,371
+6,489
+25% +$499K 0.06% 436
2017
Q4 		$1.53M Buy
+25,882
New +$1.3M 0.03% 716
2017
Q1 		– Sell
-142,669
Closed -$4.78M – 1411
2016
Q4 		$4.78M Buy
142,669
+4,917
+4% +$141K 0.17% 116
2016
Q3 		$3.67M Buy
137,752
+63,980
+87% +$1.49M 0.11% 221
2016
Q2 		$1.63M Sell
73,772
-48,685
-40% -$1.27M 0.05% 403
2016
Q1 		$3.6M Buy
122,457
+62,165
+103% +$1.73M 0.1% 251
2015
Q4 		$2.02M Buy
+60,292
New +$1.96M 0.05% 394

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Oxford Asset Management's ENTA Position: Q1 2025 in Review

Oxford Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2025, closing a stake of 23,762 shares — an estimated $137K sold.

Oxford Asset Management first reported a position in ENTA in Q4 2015 and held it in 13 quarters. The position peaked at $4.78M in Q4 2016. 109 funds tracked by Wall St. Rank hold ENTA as of Q1 2025.

  • Oxford Asset Management reported no remaining Enanta Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Oxford Asset Management sold 23,762 Enanta Pharmaceuticals shares in Q1 2025, an estimated $137K.
  • Oxford Asset Management first reported a position in Enanta Pharmaceuticals in Q4 2015 and held it in 13 quarters.
  • Oxford Asset Management's Enanta Pharmaceuticals position peaked at $4.78M in Q4 2016.
  • 109 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2025.

Based on Oxford Asset Management's 13F filing for Q1 2025, filed 15 May 2025.